Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination
LYMPHIR shows 86% response rate when combined with CAR-T therapy in relapsed or refractory diffuse large B-cell lymphoma patients.
LSD Just Beat Phase 3 Twice. Now Comes the Hard Part.
Definium's DT120 cleared Phase 3 in both MDD and GAD. As a ketamine PI who's treated 30,000+ patients, here's...
AI Clinical Decision Support Is Outrunning Its Own Evidence Base: What Trial Operators Need to Know Now
71% of U.S. hospitals now run predictive AI in their EHRs, but a 9,600-patient Kenya trial shows improved clinician...
AI Clinical Decision Support Is Everywhere. The Evidence Base Is Not.
71% of US hospitals now deploy predictive AI, but validation frameworks lag dangerously behind. Here's what that gap means...
Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028
Nektar raises $373.8M to fund rezpegaldesleukin Phase 3 trials through 2028, with data readouts expected mid-2028 in atopic dermatitis.
Inhibrx Reports Q2 2026 Loss, Advances Ozekibart Toward FDA Decision
Inhibrx advances ozekibart toward FDA approval in chondrosarcoma with April 2027 PDUFA date while expanding colorectal cancer trials.
Atrium Therapeutics Opens Enrollment in PRKAG2 Syndrome Trial Funded by BMS Collaboration
Atrium Therapeutics opens enrollment in PRKAG2 Syndrome Trial for ATR 1072, an siRNA candidate targeting rare cardiomyopathy.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 EGFR Exon 20 Trial
Zipalertinib plus chemotherapy met its primary progression-free survival endpoint in the Phase 3 REZILIENT3 trial for EGFR exon 20...
FDA Clears Denifanstat Phase 3 Trial for Moderate to Severe Acne
FDA clears denifanstat Phase 3 trial for moderate to severe acne. The FASN inhibitor showed 61.3% lesion reduction in...
The 82x ROI Claim Looks Great on a Slide Deck — But Who’s Paying for the Infrastructure at the Site?
Tufts CSDD says AI monitoring agents deliver 82x ROI in Phase 3 oncology. But that number assumes sites can...